Related Experiment Video

Updated: Aug 17, 2026

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

17.5K

Case Report: Management of Recurrent Ovarian Squamous Cell Carcinoma With PD-1 Inhibitor

Xiao-Chen Song1, Yong-Xue Wang1, Mei Yu1

  • 1Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Obstetrics & Gynecologic Diseases, Beijing, China.

Frontiers in Oncology
|March 31, 2022
PubMed

Insights

Ovarian squamous cell carcinoma (SCC) arising from mature cystic teratomas is rare. A recurrent case showed a PIK3CA gene variation and high PD-L1 expression, responding well to chemotherapy and PD-1 immunotherapy.

Area of Science:

  • Gynecologic Oncology
  • Oncogenesis
  • Immunotherapy

Background:

  • Ovarian mature cystic teratomas (OMCT) rarely undergo malignant transformation into squamous cell carcinoma (SCC).
  • Management of recurrent ovarian SCC presents challenges, with underlying genetic drivers often unclear.
  • Understanding genetic mutations and biomarkers is crucial for effective treatment strategies.

Observation:

  • A patient with recurrent ovarian SCC originating from an OMCT was identified.
  • The tumor exhibited a PIK3CA gene variation.
  • Immunohistochemical analysis revealed programmed death-ligand 1 (PD-L1) expression exceeding 10%.

Findings:

  • The patient received platinum-based chemotherapy combined with programmed death 1 (PD-1) immunotherapy.
  • Clinical remission was achieved following this treatment regimen.
  • This suggests a potential therapeutic benefit of PD-1 blockade in this specific subset of ovarian SCC.

Implications:

  • This case highlights the PIK3CA gene variation as a potential factor in ovarian SCC development or progression.
  • High PD-L1 expression may predict response to PD-1 immunotherapy in recurrent ovarian SCC.
  • Further research into genetic mutations and immunotherapy targets is warranted for rare ovarian malignancies.
Keywords:
PD-1 inhibitorchemotherapyimmunotherapy combined therapyovarian squamous cell carcinomarecurrence

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.4K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...